FDA granted Fast Track designation to immuno-oncology products Toca 511 and Toca FC, developed by Tocagen Inc., for the treatment of recurrent high grade glioma, including glioblastoma and anaplastic astrocytoma. A study in this indication is planned for later this year, according to Tocagen.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
